The relationship between serum tumor-associated trypsin inhibitor levels and clinicopathological parameters in patients with gastric cancer

Kemik, Özgür; Kemik, A.; SUMER, Aziz; Almalı, Necat; Gurluler, E.; Gures, N.; Purisa, S.; ADAS, G.; DOGAN, Y.; TUZUN, S.

The relationship between serum tumor-associated trypsin inhibitor levels and clinicopathological parameters in patients with gastric cancer

Atıf İçin Kopyala

Kemik Ö. , Kemik A., SUMER A. , Almalı N. , Gurluler E., Gures N., et al.

EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES, cilt.17, ss.2923-2928, 2013 (SCI İndekslerine Giren Dergi)

Cilt numarası: 17 Konu: 21
Basım Tarihi: 2013
Dergi Adı: EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES
Sayfa Sayısı: ss.2923-2928

Özet

BACKGROUND: Tumor-associated trypsin inhibitor (TATI) is expressed with trypsinogen in tumors. We studied the clinical-pathologic association and significance of preoperative serum levels of TATI in gastric cancer patients.